---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-25-000051"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:59:29.587344+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma Q2 net loss $12.9M; cash $71.8M; ADR program termination planned

## Summary
- Net loss $12.9M ($0.23) vs net income $14.8M ($0.27) in Q2 2024; revenue $48K vs $24.1M.
- Cash $71.8M expected to fund operations into 2027; R&D $8.8M up from $5.3M on Phase 2 trials.
- Phase 2 Seabreeze STAT asthma/COPD studies recruiting; topline data expected H1 2026.
- Simcere submitted NDA in China for rademikibart (AD); Connect eligible for up to $110M milestones.
- Plans to terminate ADR program by Sep 2, 2025; ordinary shares to list on Nasdaq under CNTB.

## SEC filing metadata
- accession: 0001835268-25-000051
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000051/0001835268-25-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000051/cntb-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-25-000051
- JSON: https://secwatch.observer/filing/0001835268-25-000051.json
- Plain text: https://secwatch.observer/filing/0001835268-25-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.